Section 33-06-01-01 - Reportable conditionsAll reports and information concerning reportable conditions are confidential and not open to inspection. The following designated reportable conditions must be reported to the department of health and human services by the persons designated in chapter 33-06-02. If any reportable condition is designated by an asterisk, an appropriate sample or isolate must be submitted to the public health laboratory in addition to the required report.
1. Acute flaccid myelitis.8. Cancer, all malignant and in situ carcinomas; in addition, all benign cancers of the central nervous system, pituitary gland, pineal gland, and craniopharyngeal duct. Carcinoma in situ of the cervix is not collected. Basal or squamous cell carcinoma is not collected unless diagnosed in the labia, clitoris, vulva, prepuce, penis, or scrotum.10. CD4 test results (all).11. Chickenpox (varicella).12. Chlamydial infections.14. Cluster of severe or unexplained illness or deaths.16. Creutzfeldt-Jakob disease.17. Critical congenital heart disease (CCHD).21. E. coli, shiga toxin-producing*.22. Fetal alcohol syndrome (FAS).23. Foodborne or waterborne outbreaks.27. Haemophilus influenzae infection (invasive infection with haemophilus influenzae isolated from blood, cerebral spinal fluid, or other normal sterile site)*.29. Hemolytic uremic syndrome.30. Hepatitis (A*, B, C, D, and E), including hepatitis B and C nucleic acid test result (detectable or nondetectable) and hepatitis C genotype results.31. Human immunodeficiency virus (HIV) infection, including acquired immunodeficiency syndrome (AIDS). (Any positive HIV test result, including gene sequencing and drug resistance patterns.) Human immunodeficiency virus (HIV) nucleic acid test result (including nondetectable).32. Influenza (electronic laboratory reporting, novel cases, and pediatric deaths)*.33. Laboratory incidences involving the possible release of category A bioterrorism agents or novel influenza viruses into the laboratory environment.34. Lead blood level results (all).41. Meningococcal disease (invasive infection with Neisseria meningitidis isolated from blood, cerebral spinal fluid, or other normal sterile site)*.43. Neonatal abstinence syndrome (NAS).44. Nipah viral infections*.45. Nosocomial outbreaks.46. Novel severe acute illness*.47. Organisms resistant to carbapenem or with emerging antimicrobial resistance*.53. Pregnancy in a person infected with hepatitis B or C, HIV, or syphilis.55. Rabies (animal or human*), all results.56. Respiratory panel test result (electronic laboratory reporting).57. Respiratory syncytial virus (electronic laboratory reporting and pediatric deaths).60. Scabies outbreaks in institutions.61. Severe acute respiratory syndrome-associated coronavirus disease (electronic laboratory reporting and pediatric deaths)*.63. Staphylococcus aureus, vancomycin resistant and intermediate resistant (VRSA and VISA)*.64. Staphylococcus enterotoxin B intoxication*.65. Streptococcus pneumoniae infections (invasive infection isolated from blood, cerebral spinal fluid, or other normal sterile site)*.66. Suicide and suicide attempts.71. Tuberculosis (tuberculosis infection caused by Mycobacterium tuberculosis or Mycobacterium bovis)*. Laboratories that receive specimens for tuberculosis testing shall report all results obtained by an appropriate procedure. This includes all smear results for acid-fast bacilli, results of cultures to look for M. tuberculosis complex, and results of rapid methodologies, including nucleic acid amplifications which are performed when M. tuberculosis complex is suspected (only via electronic laboratory reporting). Positive results of tests performed by purified protein derivative antigen and all results by any other test approved for the purpose of identifying tuberculosis infection, (i.e. interferon gamma release assay) with corresponding values as available.73. Tumors of the central nervous system.75. Unexplained or emerging critical illness or death.78. Viral hemorrhagic fevers.79. Weapons of mass destruction suspected event.N.D. Admin Code 33-06-01-01
Amended effective May 1, 1984; December 1, 1986; January 1, 1988; January 1, 1989; October 1, 1990; January 1, 1991; February 1, 1992; May 1, 1994; January 1, 1995; July 1, 1996; February 1, 2000; August 1, 2002; March 1, 2003; July 1, 2004; April 1, 2007; January 1, 2011.Amended by Administrative Rules Supplement 367, January 2018, effective 1/1/2018.Amended by Administrative Rules Supplement 374, October 2019, effective 10/1/2019.Amended by Administrative Rules Supplement 2023-391, January 2024, effective 1/1/2024.General Authority: NDCC 23-07-01
Law Implemented: NDCC 23-07-01